Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01FX18
|
| gptkbp:countryOfOperation |
gptkb:United_States
|
| gptkbp:genericName |
gptkb:teprotumumab
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tepezza
|
| gptkbp:indication |
gptkb:Graves'_orbitopathy
|
| gptkbp:legalStatus |
Rx-only
|
| gptkbp:manufacturer |
gptkb:Horizon_Therapeutics
|
| gptkbp:mechanismOfAction |
insulin-like growth factor-1 receptor antagonist
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
hearing impairment
nausea diarrhea fatigue alopecia muscle spasm |
| gptkbp:usedFor |
thyroid eye disease
|
| gptkbp:bfsParent |
gptkb:Horizon_Therapeutics
|
| gptkbp:bfsLayer |
7
|